Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE: CLVT) has announced the pricing of an underwritten public offering of 25,000,000 ordinary shares by affiliated funds of Onex Corporation and Baring Private Equity Asia. The offering is set to close on September 14, 2021, pending customary conditions. An additional 3,750,000 shares may be purchased at the underwriters' discretion. Clarivate will not sell any shares, with proceeds solely benefiting the Selling Shareholders. Citigroup and Barclays are acting as joint book-running managers for this offering.
On September 9, 2021, Clarivate Plc (NYSE: CLVT) announced an underwritten public offering of 25 million ordinary shares, managed by Citigroup and Barclays. The offering includes a 30-day option for underwriters to purchase an additional 3.75 million shares. The proceeds from this offering will be received entirely by the Selling Shareholders, Onex Corporation and Baring Private Equity Asia Group Ltd. The sale will occur under an effective shelf registration statement, and investors are encouraged to review all related documents filed with the SEC for complete information.
Clarivate Plc (NYSE: CLVT) announced that Jerre Stead, Executive Chairman and CEO, along with CFO Richard Hanks, will speak at the Barclays Global Financial Services Conference on September 15, 2021, at 11:15 AM ET. A live webcast will be available on their Investor Relations page, with a replay accessible for 30 days post-event. Clarivate is dedicated to accelerating innovation by providing trusted information and insights to help customers navigate complex problems in science and intellectual property.
On August 19, 2021, Clarivate Plc (NYSE: CLVT) announced the successful settlement of private exchange offers for its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. Approximately 92.1% of these notes were tendered, allowing the issuance of new notes totaling around $921 million each. The new notes extend the redemption deadline to April 29, 2022. Additionally, a notice of redemption for untendered notes was sent out, with a redemption date set for August 23, 2021. These offers were conducted without registration under the U.S. Securities Act, targeting eligible holders only.
Clarivate announced the expiration of two private exchange offers for outstanding notes as of August 13, 2021. The offers, which affected the 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, allowed for the exchange of old notes for new notes with an extended redemption date to April 29, 2022. A principal amount of $920,897,000 for the 3.875% notes and $920,349,000 for the 4.875% notes is expected to be accepted. The settlement date is anticipated on August 19, 2021, with no cash proceeds to Clarivate from the exchange.
Clarivate Plc (NYSE: CLVT) has announced an exchange offer for two series of its outstanding notes, totaling $2 billion, as part of its ongoing acquisition of ProQuest. The exchange is in response to a second request for documents from the FTC, extending the acquisition completion date to December 31, 2021. If the acquisition is not finalized by this date, the company may redeem the old notes. The new notes will mirror the old ones, with terms extending up to April 29, 2022, and will mature shortly after the old notes. The exchange offers are set to expire on August 13, 2021.
Clarivate Plc (NYSE:CLVT) has acquired Bioinfogate, a provider of analytics solutions in life sciences, including the OFF-X™ portal. The OFF-X portal is a significant resource, containing over 1.2 million safety alerts related to 23,000 drugs and biologics. This acquisition aims to enhance drug toxicity data integration across the life science cycle, allowing for improved decision-making in drug development. Although financial terms were not disclosed, the acquisition is expected to strengthen Clarivate's offerings, particularly in translational safety intelligence.
Clarivate Plc (NYSE: CLVT; CLVT PR A) announced a $250 million share repurchase program to be executed through October 31, 2021. The Board of Directors expressed confidence in the company's growth prospects and stated that this buyback represents an attractive investment opportunity. The purchases will be funded with existing cash balances, reflecting strong earnings and cash flow, as noted by Executive Chairman and CEO Jerre Stead.
Clarivate reported strong Q2 2021 results, with revenues of $445.6 million, a 62.9% increase year-over-year. Adjusted EBITDA reached $189.0 million (up 88.8%). Despite a net loss of $82.2 million, adjusted net income was $110.0 million, a 58.3% rise. The company saw organic revenue growth of 5% at constant currency. Cash flow from operations increased to $261.7 million. Looking ahead, Clarivate expects organic revenue growth for 2021 to be at the upper end of 6% to 8%.
Clarivate Plc (NYSE: CLVT) has launched the Cortellis Supply Chain Network™, aimed at enhancing supply chain efficiency in the biopharma sector. This platform connects over 70,000 buyers and sellers, facilitating better identification of partners and management of procurement processes. The initiative addresses vulnerabilities exposed by the COVID-19 pandemic, which highlighted the need for greater supply chain transparency. By providing continuously updated manufacturing data and insights on supply risks, the network aims to ensure more accessible therapies for patients.